What Do New China Biotech Curbs Mean For Merck (MRK) Stock?

Merck (NYSE:MRK) faces new U.S. Treasury restrictions on collaborations with certain Chinese biotech and AI firms announced in October 2026. This policy move targets U.S. investment and partnership flows into Chinese companies involved in advanced therapeutics and data-driven drug research. Limits on China partnerships could affect how Merck sources future cancer drug candidates and external research programs from that market. There is more to Merck than the new U.S. Treasury curbs on China...